Na-K-CI +协同转运蛋白作为药物靶点的研究进展  

Research progress of Na-K-Cl co-transporter as a drug target

作　　者：贺倩 孙丹丹 谢永臻 张为 梁柏堂 HE Qian;SUN Dandan;XIE Yongzhen;ZHANG Wei;LIANG Baitang(Aurora Discovery Inc.Foshan,Guangdong 528000.China)

机构地区：[1]药明激创<佛山〉生物科技有限公司同,广东佛山528000

出　　处：《医药前沿》2022年第28期21-23,共3页Journal of Frontiers of Medicine

基　　金：佛山市顺德区科学技术局《顺德区引进创新创业项目团队》(2130218002569)。

摘　　要：Na-K-C1协同转运蛋白存在于人体和动物多处组织中,在不周部位发挥着不同的功能作用,与多种疾病存在着密切关联,是有潜力的药物靶点。本文就Na-K-C1协同转运蛋白(NKCC)的蛋白结构、体内分布情况,在正常生理活动和疾病中调节作用,以及NKCC作为药物靶点的药物开发技术进行综述。Na-K-Cl co-transporter exists in many tissues of humans and animals,plays different functional roles in different parts,is closely related to a variety of diseases,and is a potential drug target.This article reviews the protein structure and in vivo distribution of Na-K-Cl co-transporter(NKCC),its regulatory role in normal physiological activities and diseases,and the drug development technology of NK CC as a drug target.

关 键 词：综述 Na-K-C1协同转运蛋白 NKCC 靶点 药物开发 离子通道阅读器ICR 

分 类 号：R91[医药卫生—药学]